GLOW

GLOW is a research peptide blend that combines BPC-157, TB-500, and GHK-Cu. It is primarily studied for skin rejuvenation, tissue repair, collagen support, hydration, and overall recovery. Research interest includes fine lines, elasticity, wound healing, scar support, hair and follicle health, and broader tissue-regeneration processes.

• Skin rejuvenation and anti-aging support
• Collagen and elastin support
• Wound and scar-repair research
• Skin tone, hydration, and elasticity
• Hair and follicle support
• Tissue repair and recovery

• Combines BPC-157, TB-500, and GHK-Cu in one blend
• May support collagen-related repair and remodeling
• May promote tissue recovery and wound-healing pathways
• May influence hydration, elasticity, and skin quality
• May support inflammation-related recovery processes

Reconstitution

3 mL bacteriostatic water or no-sting water

Final concentration

About 23.3 mg/mL total blend

Source dose

15 units: about 2.5 mg BPC-157, 0.5 mg TB-500, and 0.5 mg GHK-Cu

Frequency

3 times per week

Research duration

8–12 weeks

Break

2–4 weeks

Administration

Subcutaneous, as noted on the sheet

Research duration on the sheet: 8–12 weeks, with a 2–4 week break noted on the sheet.

• 70 mg + 3 mL bacteriostatic or no-sting water.
• 15 units is the source reference for about 2.5 mg BPC-157, 0.5 mg TB-500, and 0.5 mg GHK-Cu.

• No dose-escalation schedule is specified on the source protocol.
• The source begins at 15 units, three times per week.

• For educational and research purposes only.
• Limited human-research data.
• Avoid use in active or recent cancer research subjects.
• Not recommended during pregnancy or breastfeeding.
• Store appropriately after reconstitution.
• The sheet notes that copper exposure should stay within the source protocol, and that additional BPC-157 or TB-500 may be studied from a separate vial.

Human research

Emerging

Animal research

Extensive

Mechanistic evidence

Strong

Long-term safety data

Limited

Completed published studies are listed below and labeled as in vitro, animal, or human research. Favorable and unfavorable results are both included, including cancer studies. This is not every paper on the compound, and it is not a recommendation or a dose.

No completed study of this blend as one product was identified. The links are completed studies of peptides in the blend.

• BPC 157 accelerates healing of a transected rat Achilles tendonAnimal

  Rats with a cut Achilles tendon recovered more function, strength, and collagen organization than saline controls.

• BPC 157 increases new-vessel growth through VEGFR2In vitro

  Human endothelial cells formed more vessel-like tubes, and rats grew more vessels in an ischemic limb. The study did not implant a tumor. New-vessel growth is the result cancer researchers watch.

• BPC 157 in mice with colon-cancer cachexiaAnimal

  Mice with C26 colon tumors. The report describes better body weight, less muscle wasting, and lower IL-6 and TNF-alpha. Tumor volume was lower on average, and that difference was not statistically significant.

• Thymosin beta-4 accelerates wound healingAnimal

  Rats. Full-thickness skin wounds closed faster, with more collagen and new blood vessels, after thymosin beta-4.

• Thymosin beta-4 in human pancreatic cancer cellsIn vitro

  Pancreatic cancer cells made more thymosin beta-4 than normal duct cells. Adding the peptide increased inflammatory signals associated with tumor support.

• Topical glycyl-L-histidyl-L-lysine copper for diabetic neuropathic ulcersHuman

  People with diabetic plantar ulcers. A topical copper-peptide gel closed more of the ulcer than the gel without the peptide. This was a skin gel, not an injection.

• GHK-Cu and growth of normal and irradiated fibroblastsIn vitro

  Human skin fibroblasts, including cells taken after radiation for head and neck cancer. GHK-Cu sped doubling and raised early growth-factor output. These were repair cells, not cancer cells.

• Topical GHK-Cu on irradiated rat woundsAnimal

  Rats after radiation. A topical GHK-Cu gel did not reduce flap injury or increase blood vessels compared with ointment alone.

• GHK and cancer-related gene expressionIn vitro

  A gene-expression database ranked GHK as reversing about 70% of a 54-gene pattern tied to aggressive colon cancer. The same paper reports that GHK-copper suppressed sarcoma 180 growth in mice. This is not a human cancer trial.

• GHK-Cu and gene expression in breast and prostate cancer cellsIn vitro

  Stored profiles of MCF7 breast cancer cells and PC3 prostate cancer cells treated with GHK-Cu showed changes in cancer-related genes. The paper does not measure tumor size.

70 mg vial. Format: Lyophilized powder.